ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2013

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,973Medicare Part D Prescriptions Filled, Including Refills

Rank: 255 out of 909

$536K Total Retail Price of All Prescriptions

Rank: 252 out of 909

379 Patients Receiving at Least One Drug in Part D
63% Patients 65 Years and Older
72% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg 81928cdb0ebe162ff75cf405bfacadd396bf3ec84bc467b6f3e612dd63daa776 Average for
this specialty
in Louisiana
Lower avg 72b1978e1dcc0b845f89d17d692cfff7aeaf8d8bce70310d8bfc535db2daf62a

Schedule Two
Controlled Substances

4% of this provider’s 379 patients filled at least one prescription for a schedule two drug, compared to an average of 2%.

Schedule Three
Controlled Substances

17% of this provider’s 379 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$54 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

26 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

B

A benzodiazepine, or tranquilizer. More » The American Geriatrics Society says these drugs increase the risk of cognitive impairment, delirium, falls and fractures in older adults.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled with Refills Prescriptions
to 65+
Patients Recieving this Drug Category For this Prescriber For All Prescribers in
This Specialty in Louisiana
AMLODIPINE BESYLATE 347 264 55 1 1
HYDROCODONE-ACETAMINOPHEN 340 122 58 S3 2 3
METFORMIN HCL 262 186 52 3 5
HYDROCHLOROTHIAZIDE 230 156 38 4 11
FUROSEMIDE 225 148 38 5 8
OMEPRAZOLE 217 127 35 6 7
SIMVASTATIN 173 138 27 7 6
CLONIDINE HCL 171 96 30 8 39
CLOPIDOGREL 162 134 24 9 18
NEXIUM 147 100 22 10 17
ZOLPIDEM TARTRATE 146 64 26 11 22
LISINOPRIL 143 103 27 12 4
ATORVASTATIN CALCIUM 136 105 27 13 9
GLIMEPIRIDE 135 117 18 14 31
LEVOTHYROXINE SODIUM 126 97 20 15 2
TRAMADOL HCL 119 86 29 16 15
BUMETANIDE 117 81 20 17 136
PRAVASTATIN SODIUM 112 83 17 18 10
METOPROLOL TARTRATE 111 97 18 19 16
AZITHROMYCIN 108 66 78 20 44
GABAPENTIN 105 82 21 21 12
VALSARTAN-HYDROCHLOROTHIAZIDE 100 51 15 22 62
AMLODIPINE BESYLATE-BENAZEPRIL 92 87* 15 23 51
MONTELUKAST SODIUM 89 65 13 24 43
DIOVAN 89 67 12 24 38
AMITRIPTYLINE HCL 88 58 14 R 26 49
METOPROLOL SUCCINATE 88 83* 21 26 19
PANTOPRAZOLE SODIUM 85 67 15 28 27
KLOR-CON 10 84 55 14 29 184
NAMENDA 82 <11 <11 30 32
ALPRAZOLAM 77 <11 <11 B 31 14
ATENOLOL 77 49 11 31 28
POTASSIUM CHLORIDE 76 62 17 33 13
HYDRALAZINE HCL 72 41 17 34 91
LISINOPRIL-HYDROCHLOROTHIAZIDE 72 <11 <11 34 24
KLOR-CON M20 69 43 13 36 78
PREDNISONE 65 22 29 37 48
LYRICA 65 <11 <11 37 63
CARISOPRODOL 63 <11 <11 R 39 79
FLUCONAZOLE 59 37 24 40 142
CRESTOR 58 <11 <11 41 26
CYCLOBENZAPRINE HCL 58 21 15 R 41 72
DIGOX 57 <11 <11 43 95
ESCITALOPRAM OXALATE 55 <11 <11 44 36
NIFEDIPINE ER 54 <11 <11 45 76
BENAZEPRIL HCL 53 <11 <11 46 47
ADVAIR DISKUS 53 <11 <11 46 56
DILTIAZEM ER 53 <11 <11 46 162
CYMBALTA 52 <11 <11 49 40
PROMETHAZINE HCL 52 20 13 R 49 114
IBUPROFEN 51 37 14 51 103
About This Data

Prescribing data from Medicare’s prescription drug benefit, known as Part D, was compiled and released by the Centers for Medicare and Medicaid Services, the federal agency that oversees the program. ProPublica combined that data with additional information released by CMS. The data for 2013 includes nearly 1.4 billion prescriptions written by 1.3 million doctors, nurses and other providers. This database lists about 410,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths of these prescriptions went to patients 65 and older; the rest were for disabled patients Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to checkup@propublica.org and we will update your information. If you have other questions about this data, send a note to checkup@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 20, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.